|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Regeneron_Pharmaceuticals
gptkb:Amgen
|
|
gptkbp:activities
|
inhibits PCS K9 protein
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:class
|
PCS K9 inhibitor
|
|
gptkbp:clinical_trial
|
gptkb:DESCARTES_trial
gptkb:FOURIER_trial
gptkb:LAPLACE-2_trial
gptkb:atherosclerotic_cardiovascular_disease
gptkb:familial_hypercholesterolemia
Phase III
|
|
gptkbp:contraindication
|
hypersensitivity to evolocumab
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:education
|
storage instructions
injection technique
side effects awareness
|
|
gptkbp:formulation
|
pre-filled syringe
autoinjector
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Repatha
|
|
gptkbp:indication
|
hyperlipidemia
cardiovascular risk reduction
|
|
gptkbp:ingredients
|
gptkb:evolocumab
C405 H609 N109 O114 S1
|
|
gptkbp:invention
|
2026
|
|
gptkbp:is_effective_against
|
reduces LDL cholesterol
reduces cardiovascular events
|
|
gptkbp:is_used_for
|
lowering cholesterol
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Amgen
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:population
|
adults
children over 10 years
|
|
gptkbp:price
|
approximately $14,000 per year
|
|
gptkbp:provides_information_on
|
gptkb:European_Society_of_Cardiology
gptkb:healthcare_organization
gptkb:American_College_of_Cardiology
|
|
gptkbp:research_focus
|
cost-effectiveness
long-term safety
comparative effectiveness
|
|
gptkbp:safety_features
|
not recommended during pregnancy
|
|
gptkbp:side_effect
|
allergic reactions
back pain
injection site reactions
flu-like symptoms
elevated liver enzymes
nasopharyngitis
myalgia
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:traded_on
|
gptkb:evolocumab
|
|
gptkbp:type_of_care
|
self-administered
|
|
gptkbp:weight
|
143.2 k Da
|